Abstract |
The dependence of cancer on an immunotolerant tumor microenvironment (TME) is well established. Immunotherapies that overcome tumor-induced immune suppression have been central to recent advancements in oncology. This is highlighted by the success of agents that interrupt PD-1 mediated immune suppression in a range of cancers. However, while PD-1 blockade has been paradigm-shifting in many malignancies, the majority of cancers show high rates of primary resistance to this approach. This has led to a rapid expansion in therapeutic targeting of other immune checkpoint molecules to provide combination immune checkpoint blockade (ICB), with one such promising approach is blockade of Lymphocyte Activation Gene 3 (LAG-3). Clinically, lymphoproliferative disorders show a wide spectrum of responses to ICB. Specific subtypes including classical Hodgkin lymphoma have demonstrated striking efficacy with anti-PD-1 therapy. Conversely, early trials of ICB have been relatively disappointing in common subtypes of Non-Hodgkin lymphoma. In this review, we describe the TME of common lymphoma subtypes with an emphasis on the role of prominent immune checkpoint molecules PD-1 and LAG3. We will also discuss current clinical evidence for ICB in lymphoma and highlight key areas for further investigation where synergistic dual checkpoint blockade of LAG-3 and PD-1 could be used to overcome ICB resistance.
|
Authors | Joshua W D Tobin, Karolina Bednarska, Ashlea Campbell, Colm Keane |
Journal | Cells
(Cells)
Vol. 10
Issue 5
(05 10 2021)
ISSN: 2073-4409 [Electronic] Switzerland |
PMID | 34068762
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Antigens, CD
- Immune Checkpoint Proteins
- Ligands
- PDCD1 protein, human
- Programmed Cell Death 1 Receptor
- Lymphocyte Activation Gene 3 Protein
- Lag3 protein, human
|
Topics |
- Animals
- Antigens, CD
(metabolism)
- Hodgkin Disease
(immunology, metabolism)
- Humans
- Immune Checkpoint Proteins
- Immune System
- Immunotherapy
- Ligands
- Lymphoma, B-Cell
(immunology, metabolism)
- Lymphoma, Large B-Cell, Diffuse
(immunology, metabolism)
- Mediastinum
(pathology)
- Nervous System
- Programmed Cell Death 1 Receptor
(metabolism)
- Tumor Microenvironment
- Lymphocyte Activation Gene 3 Protein
|